Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism

Diabetologia

Volumn 59, Issue 5, 2016, Pages 907-917

  Ahrén, Bo ^a   Foley, James E ^b  

^a LUND UNIVERSITY   (Sweden)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Dipeptidyl peptidase 4 inhibitors; GIP; GLP 1; Glucagon; Insulin; Review

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; ANTIDIABETIC AGENT;

CLINICAL EFFECTIVENESS; DIABETIC PATIENT; DRUG MECHANISM; HUMAN; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; REVIEW; ANIMAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-SECRETING CELLS; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; LIPID METABOLISM;

EID: 84958777281     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-3899-2     Document Type: Review

References (102)

1. Kahn SE, Cooper ME, Del Prato S (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383:1068–1083
2. Davidson MB (1985) Pathogenesis of impaired glucose tolerance and type II diabetes mellitus—current status. West J Med 142:219–229
3. Turner RC, Holman RR (1976) Insulin rather than glucose homoeostasis in the pathophysiology of diabetes. Lancet 1:1272–1274
4. DeFronzo RA (2010) Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53:1270–1287
5. Foley JE, Bunck MC, Möller-Goede DL et al (2011) Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 54:1985–1991
6. Dunning BE, Foley JE, Ahrén B (2005) Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 48:1700–1713
7. Del Prato S (2009) Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 26:1185–1192
8. Bolli GB, Tsalikian E, Haymond MW, Cryer P, Gerich JE (1984) Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. J Clin Invest 73:1532–1541
9. Gutnaik M, Ørskov C, Holst JJ, Ahrén B, Efendić S (1992) Antidiabetic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316–1322
10. Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-l by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952–957
11. Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE (2011) Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 13:775–783
12. Thornberry NA, Weber AE (2007) Discovery of JANUVIA (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem 7:557–568
13. Ahrén B, Simonsson E, Larsson H et al (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869–875
14. Scheen AJ (2015) A review of gliptins for 2014. Exp Opin Pharmacother 16:43–62
15. Tella SH, Rendell MS (2015) DPP-4 inhibitors: focus on safety. Exp Opin Drug Saf 14:127–140
16. Aroor A, McKarns S, Nistala R et al (2013) DPP-4 inhibitors as therapeutic modulators of immune cell function and associated cardiovascular and renal insulin resistance in obesity and diabetes. Cardiorenal Med 3:48–56
17. Ceccarelli E, Guarino EG, Meriotti D et al (2013) Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism. Front Endocrinol 4:73
18. Hocher B, Reichetzeder C, Alter ML (2012) Renal and cardiac effects of DPP4 inhibitors—from preclinical development to clinical research. Kidney Blood Press Res 36:65–84
19. Ahrén B, Pacini G, Foley JE, Schweizer A (2005) Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28:1936–1940
20. He YL, Wang Y, Bullock JM et al (2007) Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 47:633–641
21. Wu T, Ma J, Bound MJ et al (2014) Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin. Diabetes 63:2776–2787
22. Williams-Herman D, Johnson J, Teng R et al (2010) Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 12:442–451
23. Herman GA, Bergman A, Stevens C et al (2006) Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91:4612–4619
24. Rosenstock J, Aguilar-Salinas C, Klein E et al (2009) Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 25:2401–2411
25. DeFronzo RA, Hissa MN, Garber AJ et al (2009) The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 32:1649–1655
26. Pratley RE, Schweizer A, Rosenstock J et al (2008) Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 10:931–938
27. Wu YJ, Guo X, Li CJ et al (2015) Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism 64:226–235
28. Yoon KH, Shockey GR, Teng R et al (2011) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract 65:154–164
29. Sjöstrand M, Iqbal N, Lu J, Hirshberg B (2014) Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes. Diabetes Res Clin Pract 105:185–191
30. Utzschneider KM, Tong J, Montgomery B et al (2008) The dipeptidyl peptidase-4 inhibitor vildagliptin improves β-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 31:108–113
31. Bock G, Dalla Man C, Micheletto F et al (2010) The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol 73:189–196
32. D’Alessio DA, Denney AM, Hermiller LM et al (2009) Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 94:81–88
33. Vardarli I, Nauck MA, Köthe LD et al (2011) Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 96:945–954
34. Aaboe K, Knop FK, Vilsbøll T et al (2010) Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 12:323–333
35. Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA (2014) Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose. Diabetes 63:663–674
36. Rosenstock J, Foley JE, Rendell M et al (2008) Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 31:30–35
37. Balas B, Baig MR, Watson C et al (2007) The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92:1249–1255
38. Scherbaum WA, Schweizer A, Mari A et al (2008) Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 10:1114–1124
39. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ (2007) Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30:890–895
40. Garber AJ, Foley JE, Banerji MA et al (2008) Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 10:1047–1056
41. Williams-Herman D, Xu L, Teng R et al (2012) Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 14:67–76
42. Mari A, Sallas WM, He YL et al (2005) Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888–4894
43. Mari A, Scherbaum WA, Nilsson PM et al (2008) Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 93:103–109
44. Ferrannini E, Mari A (2014) β-Cell function in type 2 diabetes. Metabolism 63:1217–1227
45. El-Ouaghlidi A, Rehring E, Holst JJ et al (2007) The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 92:4165–4171
46. Muscelli E, Casolaro A, Gastaldelli A et al (2012) Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 97:2818–2826
47. Vilsbøll T, Rosenstock J, Yki-Järvinen H et al (2010) Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 12:167–177
48. van Raalte DH, van Genugten RE, Eliasson B et al (2014) The effect of alogliptin and pioglitazone combination on various aspects of β-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol 170:565–574
49. Kahn SE, Carr DB, Faulenbach MV, Utzschneider KM (2008) An examination of β-cell function measures and their potential use for estimating beta-cell mass. Diabetes Obes Metab 10(Suppl 4):63–76
50. Omar BA, Vikman J, Sörhede Winzell M et al (2013) Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase 4 inhibitor vildagliptin in an advanced age diet induced obesity mouse model. Diabetologia 56:1752–1760
51. Retnakaran R, Qi Y, Opsteen C, Vivero E, Zinman B (2010) Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab 12:909–915
52. Ahrén B, Schweizer A, Dejager S et al (2009) Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 94:1236–1243
53. Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP (2007) Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 9:186–193
54. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA (2011) Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 13:258–267
55. Ahrén B (2015) Glucagon—early breakthroughs and recent discoveries. Peptides 67:74–81
56. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078–2084
57. Vella A, Bock G, Giesler PD et al (2007) Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56:1475–1480
58. Azuma K, Rádiková Z, Mancino J et al (2008) Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 93:459–464
59. Man CD, Bock G, Giesler PD et al (2009) Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care 32:14–18
60. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L (2008) Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 24:2943–2952
61. Hansen L, Jobal N, Ekholm E, Cook W, Hirschberg B (2014) Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract 20:1187–1197
62. Ahrén B, Foley JE, Ferrannini E et al (2010) Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 33:730–732
63. Meier JJ, Gallwitz B, Siepmann N et al (2003) Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46:798–801
64. Vilsbøll T, Krarup T, Madsbad S, Holst JJ (2003) Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114:115–121
65. Ravier MA, Rutter GA (2005) Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic α-cells. Diabetes 54:1789–1797
66. Foley JE, Ligueros-Saylan M, He YL (2008) Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res 40:727–730
67. Farngren J, Persson M, Schweizer A, Foley JE, Ahrén B (2012) Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab 97:3799–3806
68. de Heer J, Rasmussen C, Coy DH, Holst JJ (2008) Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51:2263–2270
69. Farngren J, Persson M, Schweizer A, Foley JE, Ahrén B (2014) Glucagon dynamics during hypoglycemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. Diabet Obes Metab 16:812–818
70. Christensen M, Vedtofte L, Hot JJ, Vilsbøll T, Knop FK (2011) Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60:3103–3109
71. Malmgren S, Ahrén B (2015) DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice. Diabetologia 58:1091–1099
72. Waget A, Cabout C, Masseboeuf M et al (2011) Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 152:3018–3029
73. Taylor R, Magnusson I, Rothman DL et al (1996) Direct assessment of liver glycogen storage by 13C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects. J Clin Invest 97:126–132
74. Solis-Herrera C, Triplitt C, Garduno-Garcia Jde J, Adams J, DeFronzo RA, Cersosimo E (2013) Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study. Diabetes Care 36:2756–2762
75. Macauley M, Hollingsworth KG, Smith FE et al (2015) Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab 100:1578–1585
76. Schweizer A, Foley JE, Kothny W, Ahrén B (2013) Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin. Vasc Health Risk Manag 9:57–64
77. Liu L, Omar B, Marchetti P, Ahrén B (2014) Dipeptidyl peptidase-4 (DPP-4): localization and activity in human and rodent islets. Biochem Biophys Res Comun 453:398–404
78. Marchetti P, Lupi R, Bugliani M et al (2012) A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55:3262–3272
79. Omar BA, Liehua L, Yamada Y, Seino Y, Marchetti P, Ahrén B (2014) Dipeptidyl peptidase-4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from type 2 diabetic individuals. Diabetologia 57:1876–1883
80. Shah P, Ardestani A, Dharmadhikari G et al (2013) The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization. J Clin Endocrinol Metab 98:E1163–E1172
81. Boschmann M, Engeli S, Dobberstein K et al (2009) Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 94:846–852
82. Matikainen N, Mänttäri S, Schweizer A et al (2006) Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49:2049–2057
83. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P (2011) Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 13:366–373
84. Eliasson B, Möller-Goede D, Eeg-Olofsson K et al (2012) Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 55:915–925
85. Kojima Y, Kaga H, Hayashi S et al (2013) Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study. World J Diabetes 4:8–13
86. Xiao C, Dash S, Morgantini C, Patterson BW, Lewis GF (2014) Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans. Diabetes 63:2394–2401
87. Foley JE, Jordan J (2010) Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag 6:541–548
88. Bunck MC, Cornér A, Eliasson B et al (2010) One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 212:223–229
89. Matikainen N, Taskinen MR (2013) The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes. Diabet Med 30:756–757
90. Ferre P, Foufelle F (2010) Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 12(Suppl 2):82–93
91. Vella A, Bock G, Giesler PD et al (2008) The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol 69:737–744
92. Aoki K, Kamiyama H, Masuda K et al (2014) Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels. Endocr J 61:249–256
93. Wu T, Bound MJ, Zhao BR et al (2013) Effects of a d-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes. Diabetes Care 36:1913–1918
94. Stevens JE, Horowitz M, Deacon CF, Nauck M, Rayner CK, Jones KL (2012) The effects of sitagliptin on gastric emptying in healthy humans—a randomized, controlled study. Aliment Pharmacol Ther 36:379–390
95. Huang CL, Hsu CH, Huang KC, Su HY, Weng SF (2010) Preprandial single oral dose of sitagliptin does not affect circulating ghrelin and gastrin levels in normal subjects. Pharmacology 85:131–135
96. Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242
97. Jensen J, Rustad PI, Kolnes AJ, Lai YC (2011) The role of skeletal muscle glycogen breakdown for regulation of insulin sensitivity by exercise. Front Physiol 2:1–11
98. Derosa G, Carbone A, D’Angelo A et al (2012) A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. Expert Opin Pharmacother 13:2433–2442
99. Derosa G, Carbone A, Franzetti I et al (2012) Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 98:51–60
100. Derosa G, Bonaventura A, Bianchi L et al (2014) Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. Metabolism 63:957–967
101. Taskinen MR, Boren J (2015) New insights into the pathophysiology of dyslipemia in type 2 diabetes. Atherosclerosis 239:483–495
102. Blüher M, Schweizer A, Bader G, Foley JE (2014) Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes. Vasc Health Risk Manag 10:661–664